Is PT-141 (Bremelanotide) Legal in Oregon? How to Access It Legally

What Is PT-141 (Bremelanotide) and Why Does Its Legal Status Matter?

PT-141 is the research name for bremelanotide, a synthetic melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors in the brain to increase sexual motivation. Unlike PDE5 inhibitors such as sildenafil, it does not act on the vascular system directly. The FDA approved it in August 2019 under the brand name Vyleesi (AMAG Pharmaceuticals, now Palatin Technologies licensee) specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Because bremelanotide is a federally approved prescription drug, its legal status is not a gray area in the way that some research peptides are. It is not a controlled substance under the Controlled Substances Act, but it is still a prescription-only drug under 21 U.S.C. § 353(b). Dispensing, distributing, or importing it without a valid prescription violates federal law.

Why Oregon Residents Ask About Legality

Online markets sell bremelanotide as a "research chemical" in lyophilized vial form, which creates confusion. Those products are not FDA-approved, are not manufactured under cGMP standards, and their import may violate 21 U.S.C. § 331. Oregon's pharmacy practice act, ORS Chapter 689, mirrors this federal prohibition at the state level.

What Conditions Does FDA Approval Cover?

The approved indication is HSDD in premenopausal women, defined as persistently low sexual desire causing marked distress. Prescribers in Oregon may also write off-label prescriptions for other patient populations (e.g., postmenopausal women or men with sexual dysfunction) within the bounds of legitimate medical practice, a concept supported by FDA's guidance on off-label use.

Federal Legal Framework Governing Bremelanotide

Understanding the federal layer is necessary before looking at Oregon-specific rules, because federal law sets the floor for every state.

FDA Approval and the NDA Record

Vyleesi holds New Drug Application (NDA) 210557. The key trials that supported approval were RECONNECT Studies 1 and 2, two Phase 3 randomized controlled trials enrolling 1,247 premenopausal women. Published in the Journal of Sexual Medicine (Simon et al., 2019), both trials showed statistically significant improvements in satisfying sexual events and desire scores versus placebo at 24 weeks (P<0.001 for desire score in Study 1). That published efficacy record is the same evidence base prescribers in Oregon rely on when writing Vyleesi prescriptions.

Prescription-Only Status Under Federal Law

Because bremelanotide requires a prescription, a pharmacy in Oregon cannot dispense it over the counter, and no online vendor can legally ship it to an Oregon address without a corresponding valid prescription from a licensed practitioner. The FDA's Orange Book lists Vyleesi as a Reference Listed Drug with no authorized generic as of early 2025, meaning cost remains a consideration for patients.

The FDA's Bulk Drugs List and Compounding Restrictions

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacists to compound drugs for individual patients when a valid prescription exists and the compounded drug is not essentially a copy of a commercially available product. Section 503B governs outsourcing facilities that may produce larger quantities without individual prescriptions.

Bremelanotide is not currently on FDA's list of bulk drug substances that may be used in compounding under 503A for either Category 1 (nominated, clinical need demonstrated) or Category 2 (nominated, under evaluation). This matters because compounding with a bulk substance not on the approved list is technically outside the safe harbor that 503A provides. Some 503A pharmacies still compound bremelanotide under clinical-need arguments when a practitioner prescribes a specific formulation (e.g., intranasal or a different concentration) that Vyleesi does not offer, but this practice carries regulatory risk. Oregon pharmacies taking this approach should review FDA's draft guidance on 503A bulk substances and consult with the Oregon State Board of Pharmacy.

503B outsourcing facilities cannot compound bremelanotide for office stock without an individual prescription because the compound does not appear on the 503B bulk drug substances list.

Oregon State Legal Framework

Oregon does not add a second layer of scheduling or restriction on top of federal law for bremelanotide beyond what the Oregon Controlled Substances Act (ORS 475) already covers for scheduled substances. Bremelanotide is not scheduled in Oregon. The governing bodies for legal access are the Oregon State Board of Pharmacy and the Oregon Medical Board.

Oregon State Board of Pharmacy (ORS Chapter 689)

The Oregon State Board of Pharmacy licenses pharmacies and pharmacists operating in the state. A pharmacy compounding bremelanotide for Oregon patients must hold a valid Oregon pharmacy license and comply with both ORS 689.155 (compounding standards) and USP <797> sterile compounding guidelines, which were updated in 2023. The Board does not maintain a specific bremelanotide policy, but its general compounding rules require that a legitimate prescriber-patient relationship exists and that the prescription is not for a commercially available product without clinical justification.

Oregon Medical Board and Prescribing Authority

Licensed Oregon physicians, nurse practitioners, and physician assistants with prescribing authority may write bremelanotide prescriptions within the scope of a valid patient-provider relationship. The Oregon Medical Board requires that prescriptions for any drug reflect a documented medical evaluation. Prescribing bremelanotide off-label (for example, to a man with sexual dysfunction) is legally permissible under Oregon medical practice law, provided the prescriber documents clinical rationale.

Telehealth Prescribing in Oregon

Oregon adopted permanent telehealth parity rules after the COVID-19 public health emergency. An Oregon-licensed telehealth provider may conduct a synchronous audio-video visit and write a valid bremelanotide prescription, which an Oregon-licensed pharmacy can then dispense and ship. The Oregon Health Authority telehealth guidance confirms that telehealth visits satisfy the prescriber-patient relationship requirement for Rx-only drugs when a thorough evaluation is documented. Prescriptions written by out-of-state providers for Oregon patients are valid only if the provider holds an Oregon license or qualifies under interstate compact provisions.

How to Get PT-141 (Bremelanotide) Legally in Oregon

There are three practical access routes for Oregon patients.

Route 1: Vyleesi Through a Retail or Specialty Pharmacy

A prescriber writes a brand-name Vyleesi prescription. The patient fills it at any Oregon-licensed retail or specialty pharmacy, or through a mail-order pharmacy licensed to operate in Oregon. Vyleesi is approved at 1.75 mg subcutaneous auto-injector. Patients self-administer 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than once per month per the FDA-approved label. Cost without insurance typically runs $800 to $1,000 per auto-injector; manufacturer savings programs may reduce out-of-pocket costs.

Route 2: Compounded Bremelanotide from a 503A Pharmacy

Some patients and clinicians prefer compounded formulations, such as an intranasal spray or a different concentration. A 503A pharmacy holding an Oregon license may compound bremelanotide for a specific patient when a prescriber writes a prescription identifying a clinical need that the commercial product does not meet. The pharmacy must source the active pharmaceutical ingredient from an FDA-registered supplier, comply with USP <797> for sterile preparations, and not compound essentially a copy of Vyleesi. Given that bremelanotide is not on FDA's 503A bulk drug list, Oregon compounding pharmacies and prescribers accepting this route should document clinical justification carefully. The FDA's 503A guidance details the current enforcement posture.

Route 3: Telehealth Platforms Licensed in Oregon

Several telehealth platforms hold Oregon prescriber licenses and can evaluate patients for bremelanotide via synchronous video visit. After a documented evaluation, the platform's prescriber writes a prescription to a compounding or retail pharmacy licensed in Oregon. This is the most common access path for patients outside the Portland metro area. Patients should confirm that the platform's prescribers hold active Oregon licenses and that prescriptions are sent to pharmacies with Oregon licensure. The Oregon Board of Pharmacy pharmacy locator allows patients to verify pharmacy licensure.

What Is NOT Legal in Oregon

Several practices that appear common in online peptide communities violate federal or Oregon law.

Buying lyophilized bremelanotide vials labeled "for research use only" from domestic or overseas vendors and self-administering them is not legal. These products are unapproved drugs under 21 C.F.R. § 210 and § 211, are not manufactured under cGMP, and their import is prohibited under 21 U.S.C. § 381. The FDA has issued multiple import alerts for unapproved peptides entering the United States.

Asking a compounding pharmacy to fill a Vyleesi-equivalent prescription solely to reduce cost, without a clinical justification for why the commercial product is unsuitable, may violate the "essentially a copy" prohibition in 21 U.S.C. § 353a(b)(1)(D) as interpreted in FDA's draft guidance on essentially a copy.

Receiving a prescription from a provider who has not performed a documented clinical evaluation also puts the prescriber at risk of Oregon Medical Board disciplinary action under OAR 847-010-0000.

Safety, Efficacy, and Clinical Considerations

Efficacy Data from RECONNECT

The two key RECONNECT trials (Simon et al., 2019, PMID 31153774) enrolled 1,247 premenopausal women with HSDD diagnosed by structured clinical interview. At 24 weeks, bremelanotide produced a statistically significant increase from baseline in the Female Sexual Function Index desire domain score versus placebo (P<0.001) and a significant decrease in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm. Responder rates (defined as a meaningful improvement in both desire and distress) were approximately 25% for bremelanotide versus 17% for placebo, a modest but statistically significant difference.

Common Adverse Effects

The most common adverse effect in RECONNECT was nausea, occurring in approximately 40% of bremelanotide-treated participants versus 1% of placebo participants. Flushing (20%) and headache (11%) were also more frequent with bremelanotide. Transient blood pressure increases of roughly 2 mmHg systolic were observed in the hour after dosing, which is why the FDA label contraindicates use in patients with cardiovascular disease or uncontrolled hypertension. The American Heart Association notes that even modest acute BP elevations require caution in patients with pre-existing cardiovascular risk factors; prescribers should review AHA hypertension guidelines when evaluating patient suitability.

Melanocortin System and Off-Label Use in Men

Bremelanotide's MC4R agonism produces pro-erectile effects in men in addition to increasing desire. A Phase 2 study published in the Journal of Urology (Safarinejad, 2008, PMID 18436248) showed improved erectile function scores in men with psychogenic erectile dysfunction, though the study was small (N=59). Off-label prescribing for men in Oregon is legally permissible but requires documented clinical rationale. No Phase 3 data exist for male sexual dysfunction as of early 2025, so prescribers should counsel patients about the limited evidence base.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction (Wierman et al., 2010, PMID 20525906) note that centrallyacting therapies targeting the CNS may address desire-phase dysfunction in ways that peripherally acting agents cannot, which provides some scientific context for bremelanotide's mechanism even if the 2010 guidelines predate its approval.

The table below summarizes the legal access paths Oregon clinicians and patients can use, mapped against their regulatory risk level.

| Access Path | Regulatory Basis | Risk Level | |---|---|---| | Brand Vyleesi via licensed pharmacy with valid Rx | FDA NDA 210557, ORS 689 | Low | | Compounded bremelanotide via 503A pharmacy with documented clinical need | 21 U.S.C. § 353a, USP <797> | Moderate | | Telehealth Rx to licensed Oregon pharmacy | Oregon telehealth parity rules, ORS 689 | Low | | "Research chemical" vendor purchase | Not legal | High / Prohibited | | 503B office-stock compounding without individual Rx | Not eligible | High / Prohibited |

Monitoring and Follow-Up After Starting Bremelanotide

Oregon prescribers should follow the monitoring protocol outlined in the FDA prescribing information. Baseline blood pressure documentation is required. Blood pressure should be checked at the first follow-up visit, given the transient post-dose elevation. Patients reporting persistent hyperpigmentation (a known MC1R-mediated effect on melanocytes) should be evaluated by dermatology, as focal hyperpigmentation of the face, gums, and breasts was reported in 1% of trial participants with chronic use.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction states: "Bremelanotide (Vyleesi) may be offered to premenopausal women with acquired, generalized HSDD not attributable to a co-existing medical or psychiatric condition, a relationship problem, or effects of a substance." This statement directly supports the clinical framework Oregon providers should use when documenting the indication for bremelanotide prescriptions.

The North American Menopause Society (NAMS) 2021 position statement on sexual dysfunction (menopause.org) adds that clinician-assessed distress is a prerequisite for pharmacotherapy, distinguishing low desire as a clinical condition from low desire as a normal variation. Oregon prescribers should document both low desire and associated personal distress in the medical record to satisfy medical necessity criteria and Oregon Medical Board documentation standards.